Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 75

Sort by

Sort Order Select

Journal Articles

Residual mutations in epigenetic modifiers are associated with poor prognosis and high relapse rate in Acute Myeloid Leukemia

Xin Yan, Chunhua Song, Zheng Ge

Blood (2025) 146 (Supplement 1): 1740.

https://doi.org/10.1182/blood-2025-1740

Published: 2025

Journal Articles

Construction and evaluation of a prognostic model for patients with Acute Myeloid Leukemia

Feng Zhu, Yile Zhou, Yi Zhang, Liping Mao, Yinjun Lou, Yu Zhu, Zheng Ge, Zhiyong Zeng, Fengbo Jin, Tingting Liu, Haitao Xu, Yue Yao, Quanyi Lu, Jianxin Guo, Hongyan Tong, Huafeng Wang, Jie Jin

Blood (2025) 146 (Supplement 1): 1728.

https://doi.org/10.1182/blood-2025-1728

Published: 2025

Journal Articles

Adult acute myeloid leukemia with NUP98 rearrangement benefits from targeted therapy and bone marrow transplantation

Blood (2025) 146 (Supplement 1): 3391.

https://doi.org/10.1182/blood-2025-3391

Published: 2025

Journal Articles

Characteristics and clinical outcomes of ND-AML patients with bcor/bcorl1 mutations

Blood (2025) 146 (Supplement 1): 7005.

https://doi.org/10.1182/blood-2025-7005

Published: 2025

Journal Articles

High efficacy of azacitidine combined with lenalidomide in TP53 mutation-positive and other high-risk myelodysplastic neoplasms

Xin Yan, Chunhua Song, Zheng Ge

Blood (2025) 146 (Supplement 1): 2082.

https://doi.org/10.1182/blood-2025-2082

Published: 2025

Journal Articles

Clinical study reveals the high efficacy and well-tolerance of venetoclax combined with homoharringtonine, azacitidine, and cytarabine in newly diagnosed AML

Xin Yan, Yanqing Huang, Chunhua Song, Zheng Ge

Blood (2025) 146 (Supplement 1): 5224.

https://doi.org/10.1182/blood-2025-5224

Published: 2025

Journal Articles

QHRD107 (CDK9 Inhibitor), venetoclax, and azacitidine combination therapy (107VA regimen) in relapsed/refractory Acute Myeloid Leukemia: Data updates and subgroup analysis

Blood (2025) 146 (Supplement 1): 5205.

https://doi.org/10.1182/blood-2025-5205

Published: 2025

Journal Articles

Targeting the casein kinase II /ikaros axis sensitizes TKI activity by suppression of GLUT1 expression and glycolysis in ph+ ALL

Linyao Zhang, Qi Han, Huimin Xiang, Chunhua Song, Zheng Ge

Blood (2025) 146 (Supplement 1): 3305.

https://doi.org/10.1182/blood-2025-3305

Published: 2025

Journal Articles

Synergistic efficacy of EZH2 inhibitor combined with new flavonoid derivatives in AML patient-derived xenograft mouse models

Chan Yang, Qinglong Guo, Hui Hui, Hui Li, Chunhua Song, Zheng Ge

Blood (2025) 146 (Supplement 1): 3277.

https://doi.org/10.1182/blood-2025-3277

Published: 2025

Journal Articles

Safety and effectiveness of brentuximab vedotin in patients with CD30- positive B-cell lymphoma: A multicenter, prospective, observational, real-world BRAVE study in China

Jia Li, Wei Zhang, Huaqing Wang, Weili Zhao, Chuanxu Liu, Kaiyang Ding, Wenyang Huang, Zengjun Li, Xiaobo Wang, Hongmei Jing, Zheng Ge, Jianli Wang, Ziheng Guo, Huilai Zhang, Ou Bai

Blood (2025) 146 (Supplement 1): 5466.

https://doi.org/10.1182/blood-2025-5466

Published: 2025

Journal Articles

Targeting WDR5/ATAD2 signaling by the CK2/IKAROS axis demonstrates therapeutic efficacy in T-ALL

Qi Han, Yan Gu, Huimin Xiang, Linyao Zhang, Yan Wang, Chan Yang, Jun Li, Chelsea Steiner, Rosa Lapalombella, Jennifer A. Woyach, Yiping Yang, Sinisa Dovat, Chunhua Song, Zheng Ge

Blood (2025) 145 (13): 1407–1421.

https://doi.org/10.1182/blood.2024024130

Published: 2025

Includes: Supplemental data

Journal Articles

Newly-Acquired and Clonally-Increased Mutations in TP53 and RAS Pathways Promote Progressive Disease and Leukemic Transformation in Patients with Myelodysplatic Neoplasms

Xin Yan, Sr., Yulu Tian, Yan Gu, Chunhua Song, Zheng Ge

Blood (2024) 144 (Supplement 1): 3224.

https://doi.org/10.1182/blood-2024-206378

Published: 2024

Journal Articles

Targeted Therapy with CX4945 Biomimetic Nanodrug Delivery System for High-Risk B-Cell Acute Lymphoblastic Leukemia

Yan Wang, Fei Wang, Haoan Wu, Qi Han, Yu Zhang, Chunhua Song, Zheng Ge

Blood (2024) 144 (Supplement 1): 2788.

https://doi.org/10.1182/blood-2024-202461

Published: 2024

Journal Articles

Decitabine Plus All- Trans Retinoic Acid Versus Decitabine Monotherapy for Myelodysplastic Syndromes with Excess Blasts: A Multicentre, Randomized Controlled Trial

Blood (2024) 144 (Supplement 1): 663.

https://doi.org/10.1182/blood-2024-200433

Published: 2024

Journal Articles

Hetrombopag Added to Immunosuppressive Therapy in First-Line Treatment of Severe Aplastic Anemia: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial

Blood (2024) 144 (Supplement 1): 304.

https://doi.org/10.1182/blood-2024-206377

Published: 2024

Journal Articles

Synergistic Effect of EZH2 Inhibitor Dznep and Flavonoid GL-V9 in AML through Inhibition Hells and Induction of DNA Damage

Chan Yang, Qinglong Guo, Hui Hui, Hui Li, Chunhua Song, Zheng Ge

Blood (2024) 144 (Supplement 1): 4145.

https://doi.org/10.1182/blood-2024-202407

Published: 2024

Journal Articles

High Remission Rates in Relapsed/Refractory Acute Myeloid Leukemia with QHRD107 (CDK9 Inhibitor), Venetoclax, and Azacitidine Combination Therapy (107VA regimen) : Preliminary Results of a Phase 2a Study

Blood (2024) 144 (Supplement 1): 2882.

https://doi.org/10.1182/blood-2024-199412

Published: 2024

Journal Articles

Characteristics and Outcome of Diffuse Large B Cell Lymphoma: A Retrospective Single-Institutional Experience

Xue Wu, Zheng Ge

Blood (2024) 144 (Supplement 1): 6438.

https://doi.org/10.1182/blood-2024-206514

Published: 2024

Journal Articles

Dynamic Changes of Key Gene Mutations in the Disease Course of Patients with Chronic Myelomonocytic Leukemia

Xin Yan, Sr., Chunhua Song, Zheng Ge

Blood (2024) 144 (Supplement 1): 6743.

https://doi.org/10.1182/blood-2024-206853

Published: 2024

Journal Articles

A Study to Assess the Efficacy of Venetoclax Combined with Homoharringtonine and Azacitidine in De Novo Acute Myeloid Leukemia

Yanqing Huang, Chunhua Song, Zheng Ge

Blood (2024) 144 (Supplement 1): 6071.

https://doi.org/10.1182/blood-2024-205100

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Residual mutations in epigenetic modifiers are associated with poor prognosis and high relapse rate in Acute Myeloid Leukemia

Construction and evaluation of a prognostic model for patients with Acute Myeloid Leukemia

Adult acute myeloid leukemia with NUP98 rearrangement benefits from targeted therapy and bone marrow transplantation

Characteristics and clinical outcomes of ND-AML patients with bcor/bcorl1 mutations

High efficacy of azacitidine combined with lenalidomide in TP53 mutation-positive and other high-risk myelodysplastic neoplasms

Clinical study reveals the high efficacy and well-tolerance of venetoclax combined with homoharringtonine, azacitidine, and cytarabine in newly diagnosed AML

QHRD107 (CDK9 Inhibitor), venetoclax, and azacitidine combination therapy (107VA regimen) in relapsed/refractory Acute Myeloid Leukemia: Data updates and subgroup analysis

Targeting the casein kinase II /ikaros axis sensitizes TKI activity by suppression of GLUT1 expression and glycolysis in ph+ ALL

Synergistic efficacy of EZH2 inhibitor combined with new flavonoid derivatives in AML patient-derived xenograft mouse models

Safety and effectiveness of brentuximab vedotin in patients with CD30- positive B-cell lymphoma: A multicenter, prospective, observational, real-world BRAVE study in China

Targeting WDR5/ATAD2 signaling by the CK2/IKAROS axis demonstrates therapeutic efficacy in T-ALL

Newly-Acquired and Clonally-Increased Mutations in TP53 and RAS Pathways Promote Progressive Disease and Leukemic Transformation in Patients with Myelodysplatic Neoplasms

Targeted Therapy with CX4945 Biomimetic Nanodrug Delivery System for High-Risk B-Cell Acute Lymphoblastic Leukemia

Decitabine Plus All- Trans Retinoic Acid Versus Decitabine Monotherapy for Myelodysplastic Syndromes with Excess Blasts: A Multicentre, Randomized Controlled Trial

Hetrombopag Added to Immunosuppressive Therapy in First-Line Treatment of Severe Aplastic Anemia: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial

Synergistic Effect of EZH2 Inhibitor Dznep and Flavonoid GL-V9 in AML through Inhibition Hells and Induction of DNA Damage

High Remission Rates in Relapsed/Refractory Acute Myeloid Leukemia with QHRD107 (CDK9 Inhibitor), Venetoclax, and Azacitidine Combination Therapy (107VA regimen) : Preliminary Results of a Phase 2a Study

Characteristics and Outcome of Diffuse Large B Cell Lymphoma: A Retrospective Single-Institutional Experience

Dynamic Changes of Key Gene Mutations in the Disease Course of Patients with Chronic Myelomonocytic Leukemia

A Study to Assess the Efficacy of Venetoclax Combined with Homoharringtonine and Azacitidine in De Novo Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only